Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Short-term Investments (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Short-term Investments data on record, last reported at $346.6 million in Q3 2025.

  • For Q3 2025, Short-term Investments rose 40.08% year-over-year to $346.6 million; the TTM value through Sep 2025 reached $346.6 million, up 40.08%, while the annual FY2024 figure was $252.4 million, 509.88% up from the prior year.
  • Short-term Investments reached $346.6 million in Q3 2025 per DNTH's latest filing, up from $244.2 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $346.6 million in Q3 2025 and bottomed at $15.0 million in Q2 2023.
  • Average Short-term Investments over 4 years is $135.1 million, with a median of $84.6 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: tumbled 82.32% in 2023, then soared 659.33% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $60.1 million in 2022, then plummeted by 31.16% to $41.4 million in 2023, then skyrocketed by 509.88% to $252.4 million in 2024, then skyrocketed by 37.31% to $346.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $346.6 million in Q3 2025, $244.2 million in Q2 2025, and $253.1 million in Q1 2025.